Related Experiment Video
Updated: May 29, 2026
09:24
A Novel Vertebral Stabilization Method for Producing Contusive Spinal Cord Injury
Published on: January 5, 2015
Simvastatin improves spinal fusion in rats.
Bora Bostan1, Taner Güneş, Murat Aşçı
1Department of Orthopedics and Traumatology, Gaziosmanpaşa University School of Medicine, Tokat, Turkey. borabostan@gmail.com
Acta Orthopaedica Et Traumatologica Turcica
|September 13, 2011
Summary
Simvastatin, a statin drug, significantly enhanced spinal fusion in rats. This study suggests simvastatin may improve spinal fusion outcomes, particularly for elderly patients with high cholesterol.
Area of Science:
- Orthopedics
- Pharmacology
- Regenerative Medicine
Background:
- Statins are known to stimulate bone formation.
- Bone morphogenetic proteins (BMPs) play a crucial role in bone healing.
- Simvastatin is a commonly prescribed statin medication.
Purpose of the Study:
- To investigate the efficacy of orally administered simvastatin in promoting spinal fusion.
- To evaluate the impact of simvastatin on bone healing following spinal fusion surgery in a rat model.
Main Methods:
- A randomized controlled study involving 20 rats undergoing spinal fusion (L4-L6).
- The experimental group received oral simvastatin (120 mg/kg/day) for 12 weeks.
- Control group received no simvastatin treatment.
Main Results:
- Histological analysis showed significantly better fusion grades in the simvastatin group (9.30) compared to the control group (6.80) (p=0.003).
- Radiographic assessment indicated a higher incidence of Grade A fusion in the simvastatin-treated rats.
- While not statistically significant (p>0.05), the simvastatin group demonstrated a trend towards increased fusion strength.
Conclusions:
- Oral simvastatin administration promotes spinal fusion in a rat model.
- Simvastatin may serve as an effective adjunct therapy for spinal fusion procedures.
- Potential benefits for elderly patients with hypercholesterolemia undergoing spinal fusion.